Apollo Endosurgery, Inc. Announces FDA Approval of the ORBERA™ Intragastric Balloon, a Non-Surgical Solution to Assist Patients in Weight Loss – Business Wire

Residents in the United States now have a new way to help address obesity, which has become a critical health issue. The new, FDA approved ORBERA™ Managed Weight Loss System has shown that the average person lost 3.1 times the weight compared with diet and exercise alone within six months. With over 220,000 balloons distributed in over 80 countries, ORBERA™ is documenting positive results.

MKT-00879-00R01